vimarsana.com

Latest Breaking News On - Mysimba contrave - Page 1 : vimarsana.com

EMA | Benzinga

U.S. stocks finished the week slightly lower as investors gave today s poor housing data a slack, and blame it on the weather. “Investors are willing to cut the market some slack because of the weather; I m keeping my fingers crossed that the economy heats up as the weather warms up,” Jack. Read More. Don t Miss Any Updates! News Directly in Your Inbox Subscribe to:

CHMP | Benzinga

In a report published Wednesday, Leerink analyst Paul Matteis commented on Orexigen Therapeutics, Inc. (NASDAQ: OREX) and wrote that following a positive opinion from the CHMP, the company expects a final opinion from the EMA on the Mysimba (Contrave) marketing authorization application. Matteis. Read More. Don t Miss Any Updates! News Directly in Your Inbox Subscribe to:

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.